12 articles
Novartis AG sought a quia timet patent injunction against Intas Pharmaceuticals Limited before the Delhi High Court, alleging that regulatory filings and an investigation report revealed imminent infringement…
In the case of Novartis AG v. Venkata Narayana Active Ingredients Pvt. Ltd., the Madras High Court dealt with a familiar pharmaceutical patent question in a concrete factual…
The Delhi High Court dismissed Novartis’s writ petitions, ruling it had waived cross-examination by opting for rebuttal evidence. The Controller’s orders were upheld, with the patent already revoked…
The Delhi High Court upheld the validity of Novartis’s Ceritinib patent against Natco’s challenge, addressing divisional application issues and allegations of suppression. The injunction against Natco remains in…
The Bombay High Court granted Novartis an injunction against Novarish Healthcare for trademark infringement and passing off. The court found the marks deceptively similar and protected Novartis's established…
The Delhi High Court Division Bench set aside an injunction against Natco Pharma in the Novartis Eltrombopag patent dispute. The judgment provides key guidance on patent validity challenges…
This post explores how drug manufacturers leverage secondary patents to manage the patent cliff and maintain exclusivity. A detailed analysis of Entresto’s patent timeline and Indian legal context…
The post analyses significant patent and design updates for January 2022, focusing on India’s WTO patent waiver request and RGNIIPM’s training initiative. It also highlights major international patent…
This article examines recent patent litigation before the Delhi High Court, highlighting cases involving Novartis and Sulphur Mills in 2021. It discusses key judicial findings on patent validity,…
USV Pvt Ltd will acquire the JALRA trademark from Novartis for 200 crores as the patent for Vildagliptin expires. The bulletin also discusses major updates in domain name…